Actinium Pharmaceuticals, Inc. (ATNM)
Automate Your Wheel Strategy on ATNM
With Tiblio's Option Bot, you can configure your own wheel strategy including ATNM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATNM
- Rev/Share 0.026
- Book/Share 0.6095
- PB 2.3627
- Debt/Equity 0.0678
- CurrentRatio 7.3405
- ROIC -0.8001
- MktCap 44922083.0
- FreeCF/Share -0.9838
- PFCF -1.4636
- PE -1.0947
- Debt/Assets 0.0205
- DivYield 0
- ROE -1.419
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)
Published: March 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: March 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, March 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts, including allegations that: (i) Actinium “repeatedly touted the Sierra Trial's positive DCR data while downplaying the study's failure to generate statistically significant or clinically meaningful Overall Survival data; and (ii) misled investors about the importance of the Sierra Trial's poor Overall Survival data by claiming that the FDA had somehow blessed the design of the Sierra Trial …
Read More
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model - Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant prostate cancer models NEW YORK , March 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy for prostate cancer utilizing the Actinium-225 …
Read More
Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral
- Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning - Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical results, mutation agnostic mechanism and backbone therapy potential - Clinical proof of concept data from frontline AML trial under NCI CRADA, Actimab-A solid tumor program with PD-1 checkpoint inhibitors and Iomab-ACT commercial CAR-T trial together with other expected 2025 milestones to be outlined - Actinium to highlight manufacturing infrastructure development activity to support revitalized clinical programs NEW YORK , …
Read More
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechanism of action. The collaboration has two specific objectives.
Read More
About Actinium Pharmaceuticals, Inc. (ATNM)
- IPO Date 2012-12-27
- Website https://www.actiniumpharma.com
- Industry Biotechnology
- CEO Sandesh C. Seth
- Employees 31